Science & Technology
iCAD Announces New Chief Financial Officer Kevin Burns
NASHUA, N.H.--([ BUSINESS WIRE ])--iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis and workflow solutions for the early identification of cancer, announced today that Kevin Burns, 40, has joined the Companya™s Executive Leadership team as Executive Vice President of Finance and Chief Financial Officer. Mr. Burns joins iCAD having almost 20 years of global business experience at dynamic growth organizations. With a focus on growth and capital creation, Mr. Burns has a proven ability to drive results through a combination of strategic planning, innovative execution and cross-functional teamwork. Mr. Burns replaces former Executive Vice President of Finance and Chief Financial Officer, Darlene Deptula-Hicks, who recently left the position.
"I am honored to join iCAD and look forward to working with the leadership team as we continue to broaden our portfolio, expand our customer base and improve patient care throughout the cancer care cycle"
aWe are especially pleased to welcome Kevin as our Chief Financial Officer. His global management experience, track record of delivering excellent financial and operational results and team-oriented style make him ideally suited for the CFO role at iCAD as we continue to transform from an image analysis technology provider to a company focused on changing standards of care throughout the cancer care cycle,a said Ken Ferry, President and CEO of iCAD. aI look forward to Kevina™s leadership as iCAD realizes its growth potential in 2011 and beyond.a
Mr. Burns most recently served as Senior Vice President and Chief Financial Officer of AMICAS, Inc., a publicly-traded provider of image and information management solutions to the healthcare industry. Under his leadership, AMICAS delivered significant revenue and profit growth culminating in the successful sale of the company to Merge Healthcare, Inc. His prior experience includes several senior level finance positions primarily with publicly-traded technology companies including NMS Communications Corporation, MAPICS, Inc. and Marcam Corporation. Mr. Burns received his MBA in Finance and Global Management and Bachelor of Science in Finance from Babson College in Wellesley, MA.
aI am honored to join iCAD and look forward to working with the leadership team as we continue to broaden our portfolio, expand our customer base and improve patient care throughout the cancer care cycle,a said Mr. Burns.
First Quarter 2011 Financial Results Conference Call Reminder
The Company will release financial results for the three months ended March 31, 2011, following the close of the market on Tuesday, May 3, 2011. Ken Ferry and Kevin Burns will host an investor conference call beginning at 10:00 a.m. Eastern time on Wednesday, May 4, 2011.
Shareholders and other interested parties may participate in the conference call by dialing 866-362-4820 (domestic) or 617-597-5345 (international) and entering passcode 70731575 a few minutes before 10:00 a.m. ET on Wednesday, May 4, 2011. The call will also be broadcast live on the Internet at [ www.streetevents.com ], [ www.fulldisclosure.com ] and [ www.icadmed.com ].
A replay of the conference call will be accessible two hours after its completion through May 11, 2011 by dialing 888-286-8010 (domestic) or 617-801-6888 (international) and entering passcode94609121. The call will also be archived for 90 days at [ www.streetevents.com ], [ www.fulldisclosure.com ] and [ www.icadmed.com ].
About iCAD, Inc.
iCAD, Inc. is an industry-leading provider of advanced image analysis and workflow solutions that enable healthcare professionals to better serve patients by identifying pathologies and pinpointing the most prevalent cancers earlier. iCAD offers a comprehensive range of high-performance, upgradeable Computer-Aided Detection (CAD) systems and workflow solutions for mammography, Magnetic Resonance Imaging (MRI) and Computed Tomography (CT). iCAD recently acquired Xoft, Inc., developer of the Axxent® eBxa" electronic brachytherapy system. Axxent uses non-radioactive miniaturized X-ray tube technology and is FDA-cleared for the treatment of early stage breast cancer, skin cancer and endometrial cancer. The Axxent System is also cleared for use in the treatment of other cancers or conditions where radiation therapy is indicated including Intraoperative Radiation Therapy (IORT). For more information, call (877) iCADnow or visit [ www.icadmed.com ].
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:
Certain statements contained in this News Release constitute aforward-looking statementsa within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence, increased competition, customer concentration and other risks detailed in the Companya™s filings with the Securities and Exchange Commission. The words abelievea, ademonstratea, aintenda, aexpecta, aestimatea, aanticipatea, alikelya, and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at [ http://www.icadmed.com ] and on the SECa™s website at [ http://www.sec.gov ].
